When Autism and ADHD Share a Day

Key takeaways

• Autism and ADHD can occur together. Since 2013, both can be diagnosed in the same person.
• There is no rule that one must be treated first. Safety comes first. After that, the person’s own goals guide the order.
• Attention problems have many causes. Pain, poor sleep, fear, sensory overload, and hard instructions can all look like inattention.
• The main stimulant study in this group found real benefit for some children, smaller average effects, and more side effects than studies in non-autistic children.
• Adult evidence is thin. A child’s response rate is not an adult’s forecast.
• Judge a medicine by the whole day, not just by focus. Sleep, appetite, and mood are part of the result.

Zoom

The first question is usually a practical one. What would make this day easier to live?

An autistic person may need help with attention, starting tasks, acting on impulse, or losing track of time. They may also need quieter rooms, clear instructions, and a routine they can trust. A good plan can cover both.

There is no sound rule that everyone must treat autism first, or ADHD first. Safety and medical problems come first. After that, the person’s goals matter. So does the cause of the trouble, and what the treatment is likely to cost them. A plan should help someone take part in life. It should not just make them easier to manage. 1

Two diagnoses, one person

Autism and attention-deficit/hyperactivity disorder, or ADHD, can occur together. Before 2013, the rules did not allow both diagnoses at once. DSM-5 changed that. “AuDHD” is a useful community word for the overlap. It is not a separate formal diagnosis with its own test or treatment. 1

People often describe wanting a fixed plan, then getting bored with it. Or getting lost in an interest while a needed task goes untouched. Those experiences are worth raising. They are not proof of anything on their own. Many other situations produce a similar day.

An assessment needs two things. A history of how the person has developed over time. And real examples of what daily life looks like. What has been true for years? What happens at home, at school, at work? Does the trouble stay even when the task is clear and the room is comfortable? Different people may each see a different part of the same pattern.

The person’s own account matters most. Someone who uses AAC may explain their needs by typing, signing, pointing to pictures, or using a speech device. AAC means augmentative and alternative communication. A supporter can add what they have noticed. They should not replace the person’s account with a guess. Speaking easily does not mean spoken instructions are easy to follow.

Before calling it inattention

An attention problem can come from ADHD. It can also come from pain, poor sleep, fear, or a task the person does not understand. Sensory overload can pull attention toward a sound others barely hear. A language or learning difference can make a worksheet far harder than it looks. Medicines can change alertness too. 2

The timeline helps. A pattern that has lasted for years across many settings raises different questions than a sudden change after an illness. A person who used to enjoy an activity and now cannot stay awake needs a sleep and health review. They do not need more demands.

Anxiety takes up attention too. Someone can look distracted while watching for a change they fear. A written plan may settle that. If attention is still hard afterward, ADHD may still be there. One explanation does not have to crowd out the rest.

Use these examples as questions, not as a score:

These are made-up examples. They cannot tell you which diagnosis someone has. Supports can start while the assessment continues. A clear instruction or a quieter room does not have to wait for a label.

What the methylphenidate study really showed

Methylphenidate is a stimulant used for ADHD. A well-known 2005 study looked at 72 children aged 5 to 14. They had diagnoses called pervasive developmental disorders at the time, plus a lot of hyperactivity. That older category is not the same as a group recruited under today’s autism criteria. 3

The study began with a short phase to see who could tolerate the medicine. Sixty-six children went on to the blinded part. The main rating was hyperactivity. It was not whether a child became less autistic, or had a better adult life.

Thirty-five of the 72 children met the study’s definition of a response. Thirteen stopped because of side effects. Appetite loss, trouble sleeping, irritability, and emotional outbursts were the concerns. A “response” meant crossing a set line on two ratings. It did not mean every need was solved. 3

The researchers noted smaller average effects, and more people stopping for side effects, than in a separate large ADHD study. That is an indirect comparison. This trial did not randomly assign autistic and non-autistic children to test the difference. It supports careful watching. It does not predict that an autistic child will do badly on a stimulant.

Later work adds useful variety. A small 2013 trial of a long-acting methylphenidate found better ADHD ratings from parents and teachers. The group was selected and the trial was short, so it cannot speak for every autistic child. Together, these studies argue against both extremes. Stimulants are not useless here. The response is also not guaranteed to look like anyone else’s. 4

The exact product matters. An immediate-release tablet, a long-acting capsule, and a liquid are not the same thing in research terms. Their labels and daily use differ. The current Ritalin tablet label covers ADHD from age six and in adults. That does not set the approved ages for every methylphenidate product. 5

Other medicines answer other questions

Atomoxetine is a non-stimulant ADHD medicine. One trial included 128 autistic children aged 5 to 14. It compared atomoxetine and placebo, each with or without structured parent training. The medicine groups and the parent-training-only group each did better on some ADHD ratings than placebo alone. The results do not name a best combination. They do not rank safety against stimulants either. 6

That training was a real treatment. It was not a hint that parents caused the problem. It helped caregivers give clearer, steadier support. A family’s time, language, transport, work hours, and exhaustion all decide whether a program can be used at all. A plan can be evidence-based and still need reshaping to fit a household.

Long-acting guanfacine has also been studied. In a small blinded trial in children, it improved hyperactivity and impulsivity ratings more than placebo. Drowsiness, tiredness, appetite changes, and effects on blood pressure and pulse all needed watching. These were short-term ADHD results. They were not evidence of changing autism. 7

A later look at the same children did not find a clear benefit for sleep or anxiety. That was not a new trial. A medicine that makes someone sleepy has not necessarily treated insomnia. A calmer rating has not necessarily answered the person’s worry. 8

U.S. labels cover particular uses. Atomoxetine’s label includes children aged six and up, and adults. Intuniv’s pediatric evidence covers ages six to seventeen. Some autism studies enrolled younger children than those ranges. An autism diagnosis does not create a new approved use. The prescriber should say which product they mean, and whether the use is off-label. 9 10

Separate trials cannot be stacked into a reliable ladder. They studied different children, used different ratings, and followed people for different lengths of time. The choice also depends on other conditions, past treatment, whether a person can swallow a pill, and what they are willing to try.

Make side effects part of the goal

Before any medicine change, write down sleep, appetite, mood, energy, and the target task. That gives the next visit something to compare against. “Focus is better” is not enough if the person has stopped eating lunch or cannot fall asleep.

Stimulant monitoring covers appetite and growth in children, sleep, mood, blood pressure, pulse, and heart history. Atomoxetine also needs attention to mood and suicidal thoughts in children and teens. That is a boxed warning on its label. The label also lists rare serious liver injury and other cautions the prescriber should explain. 5 9

With guanfacine, ask about dizziness, fainting, daytime sleepiness, low blood pressure, and a slow pulse. Stopping it suddenly can send blood pressure up. Do not change or stop it on your own. Ask how the prescriber wants to hear about problems, and what to do about a missed dose. 10

A person may show a side effect before they can name it. Refusing meals, moving less, new distress, or dropping a loved activity all deserve a question. None of these should simply be praised as better behavior. A clinician can help sort a side effect from illness, stress, or something that was already there.

Adults need adult evidence

Adult evidence in autism is much smaller than the child evidence. It is not missing. A Dutch records study compared adults who had ADHD plus autism with adults who had ADHD alone. Both groups improved during care. The study did not find clear differences in side effects. It was not randomized, and it only included people with complete records. It cannot prove equal response or equal safety for all adults. 11

A small open trial of a long-acting liquid methylphenidate also reported benefit in selected autistic adults. There was no placebo group. Everyone in it was described as intellectually capable. That leaves big questions for adults with intellectual disability or major communication needs. 12

So clinicians often start from ordinary adult ADHD guidance and adjust for autism-related needs. A childhood response rate is not a personal forecast. An adult may care most about cooking meals, paying bills, keeping a job, or having energy left after work. Name those outcomes directly.

Choosing what to work on first

Start with an urgent health or safety problem if there is one. Otherwise, pick one difficulty that costs the person something real, and one improvement they actually want. Agree on supports that can start now. Review what has helped before, what caused harm, and what is still unknown.

When you can, change one thing at a time. That makes it easier to learn what helped. This is not a rule that delays care in a crisis, and it does not stop several needed supports from starting together. Set a review date. Decide how you will gather the person’s account, family observations, and school or work information.

Frequently asked questions

Should we treat the autism or the ADHD first? Neither has automatic priority. Safety and medical problems come first. After that, start with the difficulty that costs the most and that the person wants changed.

Will a stimulant make my child less autistic? No. These medicines were studied for attention, hyperactivity, and impulsivity. Becoming less visibly autistic is not the goal and is not the measured result.

My child reacted badly to a stimulant. Does that mean all ADHD medicines will fail? No. Different medicines act differently, and the exact product and dose matter. Tell the prescriber what happened, so the next choice can account for it.

Is AuDHD a real diagnosis? It is a useful community word, not a formal diagnosis. There is no single AuDHD test and no single AuDHD treatment.

What if my attention problems only started recently? A recent change points toward a different set of questions than a lifelong pattern. Sleep, pain, illness, medicines, and stress should be reviewed first.

Related reading on NP FADY

• Autism testing in the Inland Empire: a verified directory
• ADHD testing in the Inland Empire: a website-checked directory
• Turn one knob, then wait: a safer autism medication plan
• Adult autism diagnosis and late diagnosis
• Missed conditions and medication targets
• Autistic masking and missed diagnosis

References

1. Young S, Hollingdale J, Absoud M, et al. Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus. BMC Medicine. 2020;18:146. DOI 10.1186/s12916-020-01585-y. DOI.

2. Hyman SL, Levy SE, Myers SM; AAP Council on Children With Disabilities, Section on Developmental and Behavioral Pediatrics. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics. 2020;145:e20193447. DOI 10.1542/peds.2019-3447. DOI.

3. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders With Hyperactivity. Archives of General Psychiatry. 2005;62:1266–1274. DOI 10.1001/archpsyc.62.11.1266. DOI.

4. Pearson DA, Santos CW, Aman MG, et al. Effects of Extended Release Methylphenidate Treatment on Ratings of Attention-Deficit/Hyperactivity Disorder (ADHD) and Associated Behavior in Children with Autism Spectrum Disorders and ADHD Symptoms. Journal of Child and Adolescent Psychopharmacology. 2013;23:337–351. DOI 10.1089/cap.2012.0096. DOI.

5. Novartis Pharmaceuticals Corporation. RITALIN (methylphenidate hydrochloride) tablets: prescribing information. DailyMed. Revised February 2025 (updated February 5, 2025). Source.

6. Handen BL, Aman MG, Arnold LE, et al. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2015;54:905–915. DOI 10.1016/j.jaac.2015.08.013. DOI.

7. Scahill L, McCracken JT, King BH, et al. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal of Psychiatry. 2015;172:1197–1206. DOI 10.1176/appi.ajp.2015.15010055. DOI.

8. Politte LC, Scahill L, Figueroa J, et al. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018;43:1772–1778. DOI 10.1038/s41386-018-0039-3. DOI.

9. Eli Lilly and Company. STRATTERA (atomoxetine) capsules: prescribing information. U.S. Food and Drug Administration, NDA 021411 S-053. Revised June 2026. Source.

10. Takeda Pharmaceuticals America, Inc. INTUNIV (guanfacine) extended-release tablets: prescribing information. DailyMed. Revised June 2025 (updated June 23, 2025). Source.

11. Muit JJ, Bothof N, Kan CC. Pharmacotherapy of ADHD in Adults With Autism Spectrum Disorder: Effectiveness and Side Effects. Journal of Attention Disorders. 2020;24:215–225. DOI 10.1177/1087054719866255. DOI.

12. Joshi G, DiSalvo M, Wozniak J, et al. A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. World Journal of Biological Psychiatry. 2020;21:274–290. DOI 10.1080/15622975.2019.1679392. DOI.

---

This article is for education. It does not diagnose a condition, replace individual care, or promise services. Do not start, stop, or change any medicine without your prescribing clinician. Reading this does not create a clinician-patient relationship. Evidence checked September 8, 2026.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.